Oricell Therapeutics closed a pre-IPO funding round of more than $110 million to accelerate its GPC3-targeted autologous CAR-T for liver cancer, with a pathway toward registrational trials. The round supports expansion of Oricell’s global footprint and reinforces the company’s push to bring solid-tumor CAR-T to pivotal-stage development. Oricell’s lead asset, Ori-C101, targets GPC3 expressed on hepatocellular carcinoma cells; the company says early human testing informed next-phase planning. The pre-IPO proceeds also fund a broader pipeline that includes additional solid-tumor programs and in vivo CAR-T approaches. The financing arrives as investors continue to fund modality-heavy cell therapy platforms despite the field’s manufacturing and clinical execution challenges, making Oricell’s capital plan a bellwether for solid-tumor CAR-T readiness.